NVO
Novo Nordisk A/S
NYSE: NVO · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$42.22
+4.79% today
Updated 2026-04-30
Market cap
$187.21B
P/E ratio
11.70
P/S ratio
0.61x
EPS (TTM)
$3.61
Dividend yield
4.27%
52W range
$35 – $78
Volume
21.0M
Novo Nordisk A/S (NVO) Financial statements
SEC filings — annual and quarterly data.
Profit margin
33.10%
Operating margin
44.50%
ROE
60.70%
ROA
17.40%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $38.75B | $6.45B | 75.26% | 23.53% | 16.65% |
| 2007 | $41.89B | $8.54B | 76.60% | 21.38% | 20.38% |
| 2008 | $45.67B | $9.67B | 77.81% | 27.16% | 21.17% |
| 2009 | $51.08B | $10.77B | 79.56% | 29.24% | 21.08% |
| 2010 | $60.78B | $14.40B | 80.78% | 31.08% | 23.70% |
| 2011 | $66.35B | $17.10B | 81.03% | 33.72% | 25.77% |
| 2012 | $78.03B | $21.43B | 82.74% | 37.77% | 27.47% |
| 2013 | $83.57B | $25.18B | 83.08% | 37.68% | 30.13% |
| 2014 | $88.81B | $26.48B | 83.60% | 38.84% | 29.82% |
| 2015 | $107.93B | $34.86B | 85.00% | 45.81% | 32.30% |
| 2016 | $111.78B | $37.92B | 84.63% | 43.33% | 33.93% |
| 2017 | $111.70B | $38.13B | 84.21% | 43.84% | 34.14% |
| 2018 | $111.83B | $38.63B | 84.25% | 42.25% | 34.54% |
| 2019 | $122.02B | $38.95B | 83.54% | 43.01% | 31.92% |
| 2020 | $126.95B | $42.14B | 83.51% | 42.64% | 33.19% |
| 2021 | $140.80B | $47.76B | 83.20% | 41.65% | 33.92% |
| 2022 | $176.95B | $55.52B | 83.92% | 42.28% | 31.38% |
| 2023 | $232.26B | $83.68B | 84.60% | 44.16% | 36.03% |
| 2024 | $290.40B | $100.99B | 84.67% | 44.19% | 34.78% |
| 2025 | $309.06B | $102.43B | 80.98% | 41.30% | 33.14% |